000308548 001__ 308548
000308548 005__ 20260123120537.0
000308548 0247_ $$2doi$$a10.1016/j.euros.2025.12.018
000308548 0247_ $$2pmid$$apmid:41561489
000308548 0247_ $$2pmc$$apmc:PMC12814690
000308548 0247_ $$2ISSN$$a2666-1691
000308548 0247_ $$2ISSN$$a2666-1683
000308548 037__ $$aDKFZ-2026-00174
000308548 041__ $$aEnglish
000308548 082__ $$a610
000308548 1001_ $$aLakes, Jale$$b0
000308548 245__ $$aGenetic Testing and Imaging in Men with Familial History or Genetic Predisposition of Prostate Cancer-Introducing the Prospective 'ProFam-Risk' Study.
000308548 260__ $$a[Amsterdam]$$bElsevier ScienceDirect$$c2026
000308548 3367_ $$2DRIVER$$aarticle
000308548 3367_ $$2DataCite$$aOutput Types/Journal article
000308548 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769090316_2905628
000308548 3367_ $$2BibTeX$$aARTICLE
000308548 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000308548 3367_ $$00$$2EndNote$$aJournal Article
000308548 500__ $$a#LA:C130#
000308548 520__ $$aFamilial and genetic factors influence prostate cancer (PCa) risk, necessitating personalized prevention strategies. This study aims to establish and validate a prevention clinic (ProFam-Risk) for men with a familial or genetic risk of PCa, focusing on genetic testing, multiparametric magnetic resonance imaging (mpMRI), and psychosocial assessment. ProFam-Risk is a prospective registry and outpatient clinic at the University Hospital Düsseldorf, recruiting participants into three groups: healthy men with a familial risk (having two or more affected relatives or early-onset PCa), men with pathogenic germline variants (eg, BRCA1/2), and PCa-affected men meeting familial/genetic criteria. Participants undergo prostate-specific antigen testing, mpMRI, genetic analysis, psychosocial assessment, and receive risk-adapted recommendations for cancer prevention. Outcome measures include prevalence of pathogenic variants, PCa detection rates, and the impact of genetic counseling and mpMRI on clinical decision-making.
000308548 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000308548 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000308548 650_7 $$2Other$$aGenetic risk
000308548 650_7 $$2Other$$aMultiparametric magnetic resonance imaging
000308548 650_7 $$2Other$$aPathogenic germline variants
000308548 650_7 $$2Other$$aPersonalized screening
000308548 650_7 $$2Other$$aProstate cancer
000308548 7001_ $$aBoschheidgen, Matthias$$b1
000308548 7001_ $$aAntoch, Gerald$$b2
000308548 7001_ $$aKlett, Maike K$$b3
000308548 7001_ $$aKarger, André$$b4
000308548 7001_ $$aRoth, Regina$$b5
000308548 7001_ $$aRedler, Silke$$b6
000308548 7001_ $$aPai, Mangalore G$$b7
000308548 7001_ $$aWieczorek, Dagmar$$b8
000308548 7001_ $$aJäger, Bernadette$$b9
000308548 7001_ $$aFehm, Tanja N$$b10
000308548 7001_ $$aNiegisch, Günter$$b11
000308548 7001_ $$aRau, Tilman T$$b12
000308548 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b13$$eLast author$$udkfz
000308548 773__ $$0PERI:(DE-600)3040546-4$$a10.1016/j.euros.2025.12.018$$gVol. 84, p. 13 - 21$$p13 - 21$$tEuropean urology open science$$v84$$x2666-1691$$y2026
000308548 909CO $$ooai:inrepo02.dkfz.de:308548$$pVDB
000308548 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000308548 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000308548 9141_ $$y2026
000308548 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL OPEN SCI : 2022$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-12-04T14:46:26Z
000308548 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-12-04T14:46:26Z
000308548 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2020-12-04T14:46:26Z
000308548 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-14
000308548 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-14
000308548 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000308548 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000308548 980__ $$ajournal
000308548 980__ $$aVDB
000308548 980__ $$aI:(DE-He78)C130-20160331
000308548 980__ $$aUNRESTRICTED